How to HIV Integrase Inhibitors?

Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor,HIV integrase inhibitors,HIV integrase inhibitors: cyclic pyrimidinone compounds,HIV integrase inhibitors,HIV integrase inhibitors

HIV Integrase Inhibitors patented technology retrieval search results - Eureka

Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor

ActiveUS7211572B2Effective anti-HIV agentStrong inhibitory activityBiocideOrganic chemistryAnti-HIV AgentSide effect

The present invention relates to a nitrogen-containing fused ring compound represented by the following formula [I]wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, and an anti-HIV agent containing such compound. The compound of the present invention has an HIV integrase inhibitory activity, and is useful as an agent for the prophylaxis or treatment of AIDS, or as an anti-HIV agent. In addition, by the combined use with other anti-HIV agents such as a protease inhibitor, a reverse transcriptase inhibitor and the like, it can be a more effective anti-HIV agent. Because it shows integrase-specific high inhibitory activity, the compound can be a pharmaceutical agent safe on human body, which causes only a fewer side effects.

Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor

View all

Owner:JAPAN TOBACCO INC

HIV integrase inhibitors

ActiveUS20070111984A1Organic active ingredientsBiocideIntegrasesMedicine

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

View all

Owner:BRISTOL MYERS SQUIBB CO

HIV integrase inhibitors: cyclic pyrimidinone compounds

ActiveUS7273859B2BiocideOrganic chemistryTherapy HIVPharmaceutical drug

The invention encompasses a series of pyrimidinone compounds which inhibit HIV integrase and thereby prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses intermediates useful for making the pyrimidone compounds. Additionally, pharmaceutical compositions and methods for treating those infected with HIV are encompassed

HIV integrase inhibitors: cyclic pyrimidinone compounds

View all

Owner:BRISTOL MYERS SQUIBB CO

HIV integrase inhibitors

ActiveUS7037908B2BiocideOrganic chemistryIntegrasesMedicine

The present invention relates to a series of pyrimidine compounds of Formula I which inhibit HIV integrase and to pharmaceutical compositions and methods of treatment for AIDS or ARC using these compounds

View all

Owner:BRISTOL MYERS SQUIBB CO

HIV integrase inhibitors

ActiveUS7135467B2Inhibit functioningEffective treatmentBiocideOrganic chemistryMedicineHIV Integrase Inhibitors

Compounds useful for treating HIV are disclosed having the general formulawherein R1, R2, and B are as defined in the specification. Compositions containing the compounds and methods for using the compounds to inhibit HIV are also disclosed.

View all

Owner:BRISTOL MYERS SQUIBB CO

Bicyclic heterocycles as HIV integrase inhibitors

ActiveUS7173022B2BiocideOrganic chemistryIntegrasesVirus

The invention encompasses a series cyclic bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV

Bicyclic heterocycles as HIV integrase inhibitors

View all

Owner:BRISTOL MYERS SQUIBB CO

Bicyclic heterocycles as HIV integrase inhibitors

ActiveUS7192948B2BiocideOrganic chemistryIntegrasesTherapy HIV

The invention encompasses a series cyclic bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV

View all

Owner:BRISTOL MYERS SQUIBB CO

Bicyclic heterocycles as HIV integrase inhibitors

ActiveUS7157447B2BiocideOrganic active ingredientsIntegrasesMedicine

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV

View all

Owner:BRISTOL MYERS SQUIBB CO

HIV integrase inhibitors

ActiveUS20070112190A1BiocideOrganic chemistryIntegrasesMedicine

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

View all

Owner:BRISTOL MYERS SQUIBB CO

HIV integrase inhibitors

ActiveUS20070111985A1BiocideOrganic chemistryIntegrasesMedicine

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

View all

Owner:BRISTOL MYERS SQUIBB CO

HIV Integrase Inhibitors

ActiveUS20080004265A1BiocideOrganic chemistryIntegrasesMedicine

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

View all

Owner:BRISTOL MYERS SQUIBB CO

4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors

ActiveUS20050239819A1Promote absorptionIncreased riskBiocideOrganic chemistrySide effectReverse transcriptase

An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula [I]wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.

4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors

View all

Owner:JAPAN TOBACCO INC

HIV Integrase Inhibitors

ActiveUS20090253677A1BiocideOrganic chemistryIntegrasesMedicine

The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

View all

Owner:BRISTOL MYERS SQUIBB CO

Bicyclic heterocycles as HIV integrase inhibitors

ActiveUS20060276466A1Organic active ingredientsOrganic chemistryIntegrasesMedicine

The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

View all

Owner:BRISTOL MYERS SQUIBB CO

Bicyclic heterocycles as HIV-integrase inhibitors

ActiveUS20070049606A1BiocidePeptide/protein ingredientsIntegrasesVirus

The invention encompasses a series cyclic bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

View all

Owner:BRISTOL MYERS SQUIBB CO

Process for preparing hexahydropyrimido[1,2-a]azepine-2-carboxylates and related compounds

InactiveUS20070142635A1High yieldLow costAntiviralsPhosphorus organic compoundsCarboxylic saltHIV Integrase Inhibitors

Processes for preparing 10-amino-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydropyrimido[1,2-a]azepine-2-carboxylates and related compounds are disclosed. The preparation of carboxamide derivatives from these carboxylates is also disclosed. The carboxamides are HIV integrase inhibitors and are useful for treating HIV infection and AIDS.

Process for preparing hexahydropyrimido[1,2-a]azepine-2-carboxylates and related compounds

View all

Owner:ASKIN DAVID +5

Phosphonate analogs of HIV integrase inhibitor compounds

InactiveUS20060116356A1Increasing cellular accumulation and retentionIncrease valueBiocidePhosphorous compound active ingredientsIntegrasesMedicinal chemistry

Novel HIV integrase inhibitor compounds having at least one phosphonate group, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.

Phosphonate analogs of HIV integrase inhibitor compounds

View all

Owner:GILEAD SCI INC

6- (Heterocyclyl-substituted Benzyl) -4-Oxoquinoline Compound and Use Thereof as HIV Integrase Inhibitor

InactiveUS20080207618A1Strong inhibitory activityEffective anti-HIV agentsBiocideOrganic chemistryAnti-HIV AgentSide effect

The present invention relates to a compound represented by the following formula [I]wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutical composition, an anti-HIV agent and an HIV integrase inhibitor containing such compound. The compound of the present invention has an HIV integrase inhibitory activity, and is useful as an anti-HIV agent, or as an agent for the prophylaxis or treatment of AIDS. In addition, by the combined use with other anti-HIV agents such as a protease inhibitor, a reverse transcriptase inhibitor and the like, it can be a more effective anti-HIV agent. Because it shows integrase-specific high inhibitory activity, the compound can be a pharmaceutical agent safe on human body, which causes only a fewer side effects.

6- (Heterocyclyl-substituted Benzyl) -4-Oxoquinoline Compound and Use Thereof as HIV Integrase Inhibitor

View all

Owner:JAPAN TOBACCO INC

Crystalline forms of an HIV integrase inhibitor

InactiveUS20080280945A1Improves moisture stabilityImprove thermal stabilityBiocideOrganic chemistryMedicineHIV Integrase Inhibitors

Crystalline forms of a hexahydro-diazocinonaphthyridine trione compound are disclosed. The compound and its crystalline forms thereof are HIV integrase inhibitors useful for the prophylaxis or treatment of HIV infection or for the prophylaxis, treatment or delay in the onset or progression of AIDS.

Crystalline forms of an HIV integrase inhibitor

View all

Owner:MERCK SHARP & DOHME CORP

HIV integrase inhibitors

ActiveUS7109186B2BiocideOrganic compound preparationIntegrasesMedicine

The present invention describes novel compounds of Formula I which inhibit HIV integrase. The invention also describes compositions and treatments of AIDS or ARC by using these compounds

View all

Owner:BRISTOL MYERS SQUIBB CO

Bicyclic heterocycles as HIV integrase inhibitors

ActiveUS20050267105A1Organic active ingredientsBiocideIntegrasesMedicine

The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

View all

Owner:BRISTOL MYERS SQUIBB CO

HIV integrase inhibitors

ActiveUS20040110804A1BiocideOrganic compound preparationIntegrasesHIV Integrase Inhibitors

The present invention describes novel compounds of Formula I which inhibit HIV integrase. The invention also describes compositions and treatments of AIDS or ARC by using these compounds.

View all

Owner:BRISTOL MYERS SQUIBB CO

HIV integrase inhibitors

ActiveUS20040204498A1Broaden their knowledgeReduce riskBiocideOrganic chemistryHIV Integrase InhibitorsIntegrase inhibitor

Compounds useful for treating HIV are disclosed having the general formula wherein R<1>, R<2>, and B are as defined in the specification. Compositions containing the compounds and methods for using the compounds to inhibit HIV are also disclosed.

View all

Owner:BRISTOL MYERS SQUIBB CO

HIV integrase inhibitors: cyclic pyrimidinone compounds

ActiveUS20050256109A1BiocideOrganic chemistryIntegrasesMedicine

The invention encompasses a series of pyrimidinone compounds which inhibit HIV integrase and thereby prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses intermediates useful for making the pyrimidone compounds. Additionally, pharmaceutical compositions and methods for treating those infected with HIV are encompassed.

View all

Owner:BRISTOL MYERS SQUIBB CO

HIV integrase inhibitors

ActiveUS20040229892A1Suppression of viral loadRestoration and preservation of immunologic functionBiocideOrganic chemistryIntegrasesHIV Integrase Inhibitors

The present invention relates to a series of pyrimidine compounds of Formula I which inhibit HIV integrase and to pharmaceutical compositions and methods of treatment for AIDS or ARC using these compounds.

View all

Owner:BRISTOL MYERS SQUIBB CO

Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds

InactiveUS20080076738A1Increasing cellular accumulation and retentionIncrease valueBiocidePhosphorous compound active ingredientsIntegrasesMedicinal chemistry

Novel HIV integrase inhibitor compounds having at least one phosphonate group, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.

View all

Owner:GILEAD SCI INC

HIV integrase inhibitors

InactiveUS20070129379A1Organic active ingredientsBiocideIntegrasesMedicine

The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

View all

Owner:BRISTOL MYERS SQUIBB CO

4-oxoquinoline compounds and utilization thereof as HIV integrase inhibitors

ActiveCN1692101ALittle side effectsHighly specific inhibitory activityOrganic chemistryAntiviralsSide effectReverse transcriptase

An anti-HIV agent containing, as an active ingredient, a 4-oxoquinoline compound represented by the following formula, wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such as protease inhibitors, reverse transcriptase inhibitors and the like, the compound can become a more effective anti-HIV agent. Since the compound has high inhibitory activity specific for integrases, it can provide a safe pharmaceutical agent with a fewer side effects for human.